indication

Schizoaffective Disorder

Competitive landscape projected to LB-102’s launch window

as of 2026-07-01
Competitive set
18
12 approved · 6 pipeline
Next guided milestone
2027-02-01
LB-102 — Adjunctive MDD (Ph2) trial initiation
LB-102 protection (issued)
2037
+4 pending families to 2047

Projection timeline

actual past → guided future · protection walls overlaid
94 events
2020
2024
2028
2032
2036
2040
2044
2048
today
LB-102 launch window
guided / estimated ↑
actual ↓
focal / guidedapprovallabel expansiontrial readoutcongressnclustered events (click to expand)guided (dashed = directional)competitor patent cliff

Competitive set

resolved drugs with trials in this indication
drugRecruiting
Risperidone
US-approved 1993 · RISPERDAL
Phase 447 trials
OwnerJanssen, L.P. - Investigator Initiated Studies Program
Protection2042
drugRecruiting
Olanzapine
US-approved 1996 · ZYPREXA Intramuscular
Phase 437 trials
OwnerEli Lilly and Company
Protection2041
drugCompleted
Aripiprazole
US-approved 2002 · ABILIFY
Phase 425 trials
OwnerOtsuka Pharmaceutical Development & Commercialization, Inc.
Protection2041
drugCompleted
Ziprasidone
US-approved 2001 · Geodon
Phase 414 trials
OwnerPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Protection—
drugCompleted
Paliperidone
US-approved 2006 · Erzofri extended-release
Phase 413 trials
OwnerJohnson & Johnson
Protection2041
drugCompleted
Quetiapine
US-approved 1997 · SEROQUEL XR
Phase 413 trials
OwnerAstraZeneca
Protection—
drugRecruiting
Clozapine
US-approved 1989 · Clozaril
Phase 410 trials
OwnerShanghai Mental Health Center
Protection2028
drugCompleted
Haloperidol
US-approved 1986 · Haldol Decanoate
Phase 46 trials
OwnerJanssen, L.P. - Investigator Initiated Studies Program
Protection—
drugCompleted
Lurasidone
US-approved 2010 · Latuda
Phase 45 trials
OwnerSumitomo Pharmaceuticals America
Protection2031
drugCompleted
Asenapine
US-approved 2009 · SAPHRIS
Phase 33 trials
OwnerOrganon and Co
Protection2033
drugCompleted
Brexpiprazole (Rexulti)
US-approved 2015 · Rexulti
Phase 42 trials
OwnerOtsuka Pharmaceutical Development & Commercialization, Inc.
Protection2033
drugTerminated
Iloperidone
US-approved 2009 · FANAPT
Phase 41 trial
OwnerVanda Pharmaceuticals
Protection2031
drugCompleted
Minocycline
Pipeline · Phase 4
Phase 43 trials
OwnerShalvata Mental Health Center
Protection—
drugCompleted
Amisulpride
Pipeline · Phase 4
Phase 43 trials
OwnerSanofi
Protection2038
drugCompleted
Cannabidiol
Pipeline · Phase 2
Phase 22 trials
OwnerCentral Institute of Mental Health, Mannheim
Protection—
drugCompleted
Perphenazine
Pipeline · Phase 4
Phase 41 trial
OwnerJanssen, L.P. - Investigator Initiated Studies Program
Protection—
drugCompleted
Chlorpromazine
Pipeline · Phase 4
Phase 41 trial
OwnerMelbourne Health
Protection—
drugCompleted
Brilaroxazine
Pipeline · Phase 2
Phase 21 trial
OwnerReviva Pharmaceuticals
Protection—

Market size

prevalence as a range, not a number